Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne


  • Fabienne Ballanger Private practice, Talence, France
  • Nicole Auffret Private practice, Paris, France
  • Marie-Thérèse Leccia Department of Dermatology, Allergology and Photobiology, CHU A Michallon, Grenoble, France
  • Jean Paul Claudel Private practice, Tour, France
  • Brigitte Dréno Nantes University, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, FR-44000 Nantes, France



JAK inhibitors, acneiform lesions, drug-induced acne, JAKne, acne


Abstract is missing (Short communication)


Download data is not yet available.


Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context 2020; 9: 2020-8-5. DOI:

Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int 2022; 71: 40-46. DOI:

Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol 2022; 61: 746-754. DOI:

Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept 2021; 11: e2021145. DOI:

Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797-1810. DOI:

Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther 2022; 35: e15636. DOI:

Correia C, Antunes J, Filipe P. Management of acne induced by JAK inhibitors. Dermatol Ther 2022; 35: e15688. DOI:

King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687-1699. DOI:

Guo L, Feng S, Sun B, Jiang X, Liu Y. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34: 192-201. DOI:

Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther 2021; 34: e14563. DOI:

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014; 55: 250-254. DOI:

Aydingoz IE, Tukenmez Demirci G, Agirbasli D, Oz-Arslan D, Yenmis G. The investigation of the amounts and expressions of epidermal growth factor, epidermal growth factor receptor, and epidermal growth factor receptor gene polymorphisms in acne vulgaris. J Cosm Dermatol 2021; 20: 346-351. DOI:

Dréno B, Dagnelie MA, Khammari A, Corvec S. The skin microbiome: a new actor in inflammatory acne. Am J Clin Dermatol 2020; 21: 18-24. DOI:

Mias C, Mengeaud V, Bessou-Touya S, Duplan H. Recent advances in understanding inflammatory acne: deciphering the relationship between cutibacterium acnes and Th17 inflammatory pathway. J Eur Acad Dermatol Venereol 2023; 37: 3-11. DOI:

Dagnelie MA, Montassier E, Khammari A, Mounier C, Corvec S, Dréno B. Inflammatory skin is associated with changes in the skin microbiota composition on the back of severe acne patients. Exp Dermatol 2019; 28: 961-967. DOI:



How to Cite

Ballanger, F., Auffret, N., Leccia, M.-T., Claudel, J. P., & Dréno, B. (2023). Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne. Acta Dermato-Venereologica, 103, adv11657.



Short Communication


Most read articles by the same author(s)

1 2 > >>